HK1252937A1 - 用於治疗抑郁症的方法和试剂盒 - Google Patents

用於治疗抑郁症的方法和试剂盒 Download PDF

Info

Publication number
HK1252937A1
HK1252937A1 HK18112292.0A HK18112292A HK1252937A1 HK 1252937 A1 HK1252937 A1 HK 1252937A1 HK 18112292 A HK18112292 A HK 18112292A HK 1252937 A1 HK1252937 A1 HK 1252937A1
Authority
HK
Hong Kong
Prior art keywords
kits
methods
treatment
depression
treating depression
Prior art date
Application number
HK18112292.0A
Other languages
English (en)
Chinese (zh)
Inventor
Ivo CAERS
Ella DALY
Wayne C. Drevets
Jaskaran Singh
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1252937A1 publication Critical patent/HK1252937A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18112292.0A 2015-05-20 2016-05-20 用於治疗抑郁症的方法和试剂盒 HK1252937A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
US201562164026P 2015-05-20

Publications (1)

Publication Number Publication Date
HK1252937A1 true HK1252937A1 (zh) 2019-06-06

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112292.0A HK1252937A1 (zh) 2015-05-20 2016-05-20 用於治疗抑郁症的方法和试剂盒

Country Status (20)

Country Link
US (1) US20160338977A1 (enExample)
EP (1) EP3297618A4 (enExample)
JP (1) JP2018515557A (enExample)
KR (1) KR20180008634A (enExample)
CN (1) CN107735081A (enExample)
AU (3) AU2016263598A1 (enExample)
CA (1) CA2986477A1 (enExample)
CL (1) CL2017002904A1 (enExample)
CO (1) CO2017011564A2 (enExample)
DO (1) DOP2017000268A (enExample)
EA (1) EA201792545A1 (enExample)
EC (1) ECSP17077930A (enExample)
GT (1) GT201700246A (enExample)
HK (1) HK1252937A1 (enExample)
IL (1) IL255463A (enExample)
MA (1) MA42135A (enExample)
MX (1) MX2017014797A (enExample)
PE (1) PE20180260A1 (enExample)
PH (1) PH12017502103A1 (enExample)
WO (1) WO2016187491A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3813807A1 (en) * 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN112702995A (zh) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 治疗重度抑郁症的艾氯胺酮的治疗方案
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020178653A1 (en) * 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
CN114286674A (zh) * 2019-08-28 2022-04-05 杨森制药公司 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
KR20230018448A (ko) * 2020-05-28 2023-02-07 얀센 파마슈티카 엔.브이. 우울증의 치료 방법
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
EP2983787B1 (en) * 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
KR20170054470A (ko) * 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법

Also Published As

Publication number Publication date
US20160338977A1 (en) 2016-11-24
MX2017014797A (es) 2018-02-15
GT201700246A (es) 2019-07-29
PE20180260A1 (es) 2018-02-05
EA201792545A1 (ru) 2018-05-31
WO2016187491A1 (en) 2016-11-24
PH12017502103A1 (en) 2018-05-07
IL255463A (en) 2018-01-31
AU2016263598A1 (en) 2017-11-23
CN107735081A (zh) 2018-02-23
MA42135A (fr) 2018-03-28
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
JP2018515557A (ja) 2018-06-14
AU2021215155A1 (en) 2021-09-02
EP3297618A1 (en) 2018-03-28
KR20180008634A (ko) 2018-01-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
CL2017002904A1 (es) 2018-04-20
ECSP17077930A (es) 2018-02-28
EP3297618A4 (en) 2019-01-23
CA2986477A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
HK1252937A1 (zh) 用於治疗抑郁症的方法和试剂盒
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2023008760A (es) Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a.
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MD4710B1 (ro) Tratamente terapeutice pe bază de anamorelin
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
SA519410324B1 (ar) صياغات رش إيبينيفرين
EP4480577A3 (en) Structured elements and methods of use
PH12017550047A1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX384045B (es) (+)-azasetrón para su uso en el tratamiento de trastornos del oído.
AR105701A1 (es) Métodos y estuches para tratar la depresión
GB2546703A (en) Compounds
MX2019003002A (es) Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer.